Edinburgh Molecular Imaging, a Scottish (UK) developer of optical molecular imaging technology, closed a £4m Series A funding.
Backers included Epidarex Capital and the Scottish Investment Bank.
Co-founded by Professor Mark Bradley, Professor Chris Haslett and Dr. Kev Dhaliwal, Edinburgh Molecular Imaging is an Edinburgh BioQuarter spin-out company from the University of Edinburgh.
It is developing Optical Molecular Imaging technology focusing initially on lung conditions and then a number of other respiratory conditions, including fibrosis, lung infections and acute respiratory distress syndrome (ARDS).
FinSMEs
08/02/2014